POETIC: A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease.
Study Details
Study Description
Brief Summary
The purpose of this observational study is to measure how many people are overweight or obese amongst patients with a diagnosed cardiovascular disease (CVD). The study also aims to characterise the population including the presence of cardiovascular (CV) risk factors in a number of countries across the globe representing different geographies, ethnicities, as well as different healthcare systems.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
People with established CVD Adults diagnosed with established CVD, attending routine medical care or follow-up in a cardiology clinic. |
Other: No treatment given
No treatment given
|
Outcome Measures
Primary Outcome Measures
- Overweight and obesity among patients with established CVD pooled across all countries [At the time of patient enrolment (Day 1/Visit 1)]
% of patients
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
-
Adults, age above or equal to 18 years at the time of signing informed consent.
-
Have established CVD and equal to or greater than 1 follow up appointment following an acute event from at least one of the following:
-
Prior myocardial infarction
-
Prior stroke (ischemic or haemorrhagic stroke)
-
Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) below 85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease
Exclusion Criteria:
-
Previous participation in this study. Participation is defined as having given informed consent in this study
-
Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
-
Patients with known congenital heart disease/malformation
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Novo Nordisk Investigational Site | Plainsboro | New Jersey | United States | 08536 |
2 | Novo Nordisk Investigational Site | São Paulo | Brazil | ||
3 | Novo Nordisk Investigational Site | Ontario | Canada | ||
4 | Novo Nordisk Investigational Site | Riyadh | Saudi Arabia | ||
5 | Novo Nordisk Investigational Site | Madrid | Spain |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DAS-7537
- U1111-1283-8551